Currently Viewing:
Evidence-Based Oncology August 2016
Currently Reading
Solutions for Reducing Patient Cost Sharing for Medications
Marialanna Lee, MSC; Brian Connell; Elisa Weiss, PhD; and Louis J. DeGennaro, PhD
The Toll of Cancer Care - Clinical and Financial Toxicity
Joseph Alvarnas, MD
Does the Cost-Sharing Burden Influence Cancer Outcomes?
Surabhi Dangi-Garimella, PhD
Improve Medicare Policy to Remove Barriers to Bone Marrow and Cord Blood Transplants
Jeffrey W. Chell, MD
Proton Therapy Eliminates Unnecessary Radiation Exposure and Is Medically Necessary
Steven J. Frank, MD
Finding Solutions for Cancer Patients: The American Cancer Society's Health Insurance Assistance Service
Katherine Sharpe, MTS; Melissa Fellers; Mandi Battaglia Seiler
Precision Oncology: Why Payers Should Initiate CGP Coverage Now!
Jerry Conway and Ingrid Marino, MS, CGC
Young Adult Cancer Survivors Disproportionately Affected by Treatment Costs
Samantha Watson, MBA, and Michelle Landwehr, MPH
Patient Access to Reference Pricing Prompts Choice of Lower-Cost Testing Laboratories, Cost Savings
Surabhi Dangi-Garimella, PhD
California Experiment Will Let Pathologists Report Cancer Diagnoses in Real Time
Surabhi Dangi-Garimella, PhD
Breakthrough for Daratumumab for Use as Second-Line Treatment With Standard of Care in Multiple Myeloma
Surabhi Dangi-Garimella, PhD
NEJM Study First to Identify Mutations Responsible for Relapse in PD-1 Inhibitor—Treated Melanoma
Surabhi Dangi-Garimella, PhD
Nivolumab Passes QOL Test in Melanoma
Surabhi Dangi-Garimella, PhD
The Risk of T2D in Individuals With Benign Adrenal Tumors
Surabhi Dangi-Garimella, PhD
Paying to Make Health IT Meaningful: A Discussion at the NCCN Policy Summit
Surabhi Dangi-Garimella, PhD
Health IT Essential for the Success of Cancer Moonshot
Surabhi Dangi-Garimella, PhD
Dissolving Data Silos and Improving Access to Health IT Essential in Oncology Care
Surabhi Dangi-Garimella, PhD

Solutions for Reducing Patient Cost Sharing for Medications

Marialanna Lee, MSC; Brian Connell; Elisa Weiss, PhD; and Louis J. DeGennaro, PhD
Cost sharing for medications presents a serious access barrier for many blood cancer patients. Available solutions, if embraced by policymakers, could reduce such cost sharing with very little impact on premiums.
In 2010, Fletcher was diagnosed with chronic lymphocytic leukemia. Within 6 months of starting treatment, his disease was in remission. But this good news did not last as he relapsed just 9 months later. He began treatment again, but the results were poor: Fletcher developed congested lungs, a persistent cough, and cataracts that left him temporarily blind. So, his doctor proposed a different treatment. Exhausted, but hopeful, Fletcher was ready to try the new drug until he heard what it would cost him–$2310 out of pocket (OOP) for just 1 month of treatment. His best chance of survival would consume nearly his entire month’s take-home pay.

It was not long before Jody’s medical bills ate through her family’s savings following her diagnosis with acute lymphoblastic leukemia in 2009. To keep her cancer in remission, Jody is taking a kinase inhibitor that she will likely need for the rest of her life. But when she went to pick up her first dose at the pharmacy, she, too, was shocked to learn how much that lifesaving drug would cost her–$5640 for the first month alone. Everything that she and her husband had put away for their children’s college educations has gone to keeping Jody alive.

Besides leukemia, Fletcher and Jody have something in common: they have had health insurance throughout their cancer treatment journey. Yet, because of the high cost sharing associated with their medications, Fletcher and Jody have faced profound difficulty accessing the treatments prescribed for them. At The Leukemia & Lymphoma Society (LLS), our mission drives us to find cures for blood cancers, but we recognize that finding cures is not enough. We must also work to facilitate access to these life-saving medications, for Fletcher, Jody and many other blood cancer patients struggling to live under similar circumstances.

Over the last decade, employers and other providers of health insurance have shifted more costs onto patients due to a multitude of factors that includes the rising cost of healthcare services. This trend is especially troubling for patients living with a blood cancer diagnosis, since available treatments typically consist of high-priced specialty drugs and other cost-intensive healthcare services.

A common discussion with this cost-shifting trend is the steady increase in consumer premium payments, as employee premium contributions have increased 83% since 2006 (compared with a 54% increase for employers over the same period).1 Although premium increases have captured the headlines in recent years, the rising OOP costs that patients face, after they pay their premiums, have proven to be even more dramatic (FIGURE 1). In 2003, almost half of patients in employer-provided insurance had no deductible to cover. Ten years later, less than 20% of patients had the same benefit.2 In fact, as insurers have recognized that increasing deductibles can discourage consumers from accessing their benefits, plans have accelerated this trend. In 2015, the average deductible in an employer-provided insurance plan had increased more than 250% from a decade earlier–increasing 3-times faster than premiums over the same period.1

Of specific concern to blood cancer patients are benefit designs that increase the portion of drug costs borne by consumers. This trend is particularly striking in the Medicare Part D marketplace–in 2015, every stand-alone prescription drug plan had adopted a “specialty tier.”3 Placing a drug in a specialty tier allows the plan to charge patients a percentage of a drug’s list price rather than a fixed dollar amount and simultaneously prevents a patient from accessing Medicare’s cost-sharing appeals process. The impact on affordability is reflected in increases in the number of medications placed on the specialty tier each year. In the past 4 years alone, Part D plans have shifted 50% more drugs onto their specialty tiers,3 subjecting many patients relying on those medications to thousands of dollars in additional cost sharing.

Every day, across the country, blood cancer patients face decisions that pit their health against their family’s finances. And while policy makers, payers, and drug manufacturers engage in debates on drug pricing and a host of related topics– debates that seem far from reaching a productive resolution– patients, like Fletcher and Jody, struggle day to day to access critical medications. Evidence indicates that once cost sharing exceeds $100, adherence to prescribed medications begins to drop off significantly,4,5 likely due to the trade-off between paying for medical care and the prospect of damaging the family’s financial stability. Data also show that decreases in adherence correspond to worse outcomes6,7 and increases in costly medical interventions8,9 that, in many cases, could have been avoided with proper adherence. It is unacceptable and tragic when a patient knows that a potential cure is waiting behind the pharmacy counter but cannot receive it due to his/her inability to pay.

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!